MedTrace Logo

Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA

NCT05766969 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-03-13

No results posted yet for this study

Summary

The purpose of the study is to evaluate whether the DIA/NPR-6 is a better pain reliever in patients with diabetic neuropathic pain of the feet compared to placebo.

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

CBD/PEA

A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.

DRUG

Placebo

An inactive compound.

Sponsors & Collaborators

  • Pure Green Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Debra Kimless, MD · Pure Green Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-05
Primary Completion
2023-12-05
Completion
2023-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05766969 on ClinicalTrials.gov